Webinar on Cytokine Assays for COVID-19 Research
COVID-19 is an acute respiratory disease primarily resulting from aggressive inflammation initiated by viral replication in COVID-19 patients. Early identification of key cytokines that contribute to morbidity and mortality may result in better patient outcomes.
We invite you to join our webinar discussing how ultra-sensitive measurement of biomarkers will help us understand COVID-19 and other infectious disease immunopathology.
Time and date: Apr 28, 2020 11:00 AM (AEST)
Speaker: Greg Warner, PhD (Quanterix Corp.)
Analysis of COVID-19 immunopathology through ultrasensitive blood biomarker detection
The Quanterix ultra-sensitive Single molecule array (Simoa) technology enables researchers to measure baseline levels of important cytokines and chemokines (such as IL-6, TNFα, IL-8 and even low abundance IFNα and IL1β) well above limits of quantification and directly in blood.
Measuring early levels of these biomarkers during acute infection will deepen our understanding of cytokine storm onset and related cardiopulmonary and neurological damage. Simoa allows measurement of trace levels of IFNα, which enables separation of bacterial from viral infections. Using Simoa, researchers can monitor early signs of cytokine release syndrome in COVID-19 infections.
In this webinar, we discuss:
The key role of inflammation in disease progression and severity
• Levels of Type I and Type II interferons (IFNα, IFNγ) as early predictors of disease severity
• Pro-inflammatory cytokines (GM-CSF, IL-2, IL-6, IL-10, IL-12p70, TNFα) for early detection of severe cytokine release
• Biomarkers of chronic airway inflammatory disease (IL-4, IL-5, IL-13)
• Airway remodeling (MMP-9) in virus-induced chronic pulmonary disease
How to develop new ultrasensitive assays for viral detection and host response
• Unique Simoa homebrew kits provide the flexibility for researchers to develop single- and multiplex custom assays
• Viral protein detection with PCR-level sensitivity with the speed and convenience of immunoassays
• Serological assays to characterise host immune response, surveillance and vaccine development
• Direct detection of nucleic acids enables measurement of pathogen DNA and host miRNA biomarker levels without extraction or amplification
Characterise links between viral infection and neurological manifestations
• The role of circulating and CNS levels of chemokines (Eoxtaxin, IP-10, MCP-1) in neuroinflammation
• Multiplex measurement of serum and plasma-based biomarkers of neurodegeneration (NF-light, GFAP, UCH-L1, Tau)
• Detection of biomarkers from dried blood spots enables use of remote sample collection protocols
Measure the earliest biomarkers of myocardial injury and risk of acute and chronic cardiac disease
• Measuring changes in baseline levels of cardiac troponin I (cTnI) for determining risk of Acute Coronary Syndrome
• Detection of natriuretic peptides (NT-proBNP) in monitoring chronic cardiac disease in COVID-19
Please register here to join the discussion on how ultrasensitive measurement of biomarkers can shed light on the immunopathology of COVID-19 and other infectious diseases.